Lifecore Biomedical Q1 Earnings Call Highlights

3 weeks ago 12

MarketBeat

Wed, May 6, 2026 astatine 8:07 AM CDT 7 min read

Lifecore Biomedical logo

Lifecore Biomedical (NASDAQ:LFCR) executives highlighted caller commercialized tract transportation wins, continued outgo reductions, and improving liquidity during the company’s first-quarter 2026 net call, portion acknowledging a year-over-year gross diminution tied to antecedently discussed headwinds.

Management reiterates semipermanent targets and reaffirms 2026 outlook

President and CEO Paul Josephs said the institution continued executing connected “each of the 3 pillars” of its maturation strategy: expanding existing commercialized business, advancing improvement programs toward commercialization, and adding caller programs done concern development. Josephs said the institution believes accordant execution supports its longer-term extremity of a 12% gross compound yearly maturation complaint and EBITDA margins supra 25% by the extremity of 2029.

→ Roblox Stock Slides to New Low arsenic Safety Changes Weigh connected Outlook

Chief Financial Officer Ryan Lake reaffirmed full-year 2026 guidance, calling retired the company’s expectations for:

Total revenue: $120 cardinal to $125 million
Net loss: $35.4 cardinal to $30.9 million
Adjusted EBITDA: $20.5 cardinal to $25 million

Three caller commercialized tract transportation programs added successful the 4th

Josephs emphasized concern improvement momentum successful aboriginal 2026, noting that Lifecore signed 3 caller commercialized tract transportation programs successful the archetypal quarter.

→ 3 Emerging Markets ETFs to Maximize Exposure to High-Potential Countries

In March, the institution announced a manufacturing services statement with a caller aesthetics lawsuit for the commercialized tract transportation of a marketed, approved merchandise presently manufactured extracurricular the U.S. Josephs said the customer’s extremity is to found U.S.-based manufacturing for products sold domestically, adding that Lifecore believes the merchandise “may make commercialized gross successful 2028.”

The institution besides signed 2 CDMO manufacturing services agreements with an existing U.S. biopharmaceutical customer. One statement covers a commercialized tract transportation for a presently marketed merchandise produced by different CDMO, with Lifecore performing method transportation services to enactment regulatory support astatine its tract earlier commercialized manufacturing begins. The 2nd statement expands an existing narration for a commercialized ophthalmic merchandise Lifecore already manufactures successful 1 transportation format; the institution volition present manufacture it successful a 2nd transportation strategy presently made successful Europe. Josephs said the 2nd transportation strategy is expected to beryllium additive to existing commercialized gross for that product.

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

Read Entire Article